Patients with MS are often initially treated with moderately effective disease modifying therapies, and in case of insufficient treatment response therapy is escalated to high efficacy disease modifying therapies. In this MEDtalk Mathias Due Buron present Danish data for difference of disease activity in patients started initially on high efficacy disease modifying therapies compared to similar patients started moderately effective disease modifying therapies.

A larger decrease in total costs was observed in patients with MS who received their first disease modifying therapies early, which could potentially be explained by a slower disease progression leading to maintained work capacity.

Galina Zheleznyakova have dentified a number of different sncRNAs where further research may pave the way for identification of informative biomarkers and possible treatment targets. In this MEdtalk she present the result from the study.

The MS brain lesion atlas ( is a user-friendly interactive web interface developed to address the current challenges of understanding mechanisms driving the fate of progressive MS on lesion basis. Click and hear more about how this first MS Atlas be a new basis for treatment development.

Determination of Neurofilament light in blood may improve the assessment of patients and should be considered as part of No Evidence of Disease Activity. In this MEDtalk Jan Lycke talks about that Neurofilament light (NFL) has the potential to become the first soluble biomarker to monitor disease activity and treatment response in clinical practice of MS.

Is there a relationship between cerebrospinal fluid and blood-derived biomarkers of axonal damage and longitudinal spinal cord atrophy in individuals with progressive MS? Hear the answer from Henrik Lundell in this MEDtalk.